Cisplatin-docetaxel induction plus concurrent 3-D conformal radiotherapy and weekly chemotherapy for locally advanced non-small cell lung cancer patients: A phase ii trial

Oncology (Switzerland)

Volumn 83, Issue 6, 2012, Pages 321-328

  Poudenx, M ^a   Bondiau, P Y ^a   Chamorey, E ^a   Venissac, N ^b   Otto, J ^a   Pourel, N ^c   Castelnau, O ^d   Tessier, E ^e   De Surmont Salasc, B ^f   Berdah, J F ^g   Pop, D ^b   Michel, C ^a   Mouroux, J ^b  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b UNIVERSITY HOSPITAL OF NICE   (France)

^c INSTITUT SAINTE CATHERINE   (France)

^d INSTITUT ARNAULT TZANCK   (France)

^e Centre Azuren de Cancrologie   (France)

^f Centre Hospitalier Intercommunal   (France)

^g Clinique de l'Esprance   (France)

Author keywords

Chemotherapy; Cisplatin; Concurrent 3 D chemoradiotherapy; Docetaxel; Locally advanced non small cell lung cancer

Indexed keywords

CISPLATIN; DOCETAXEL;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED RADIOTHERAPY; DIARRHEA; DRUG EFFICACY; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; KIDNEY DISEASE; LEUKOPENIA; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LYMPH NODE DISSECTION; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RADIATION DOSE; THREE DIMENSIONAL IMAGING; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CISPLATIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RADIOTHERAPY, CONFORMAL; SURVIVAL RATE; TAXOIDS;

EID: 84866171343     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000342081     Document Type: Article

References (42)

1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Greene FL: The American Joint Committee on Cancer: updating the strategies in cancer staging. Bull Am Coll Surg 2002; 87: 13-15.
3. Potosky AL, Saxman S, Wallace RB, Lynch CF: Population variations in the initial treatment of non-small-cell lung cancer. J Clin Oncol 2004; 22: 3261-3268.
4. Albain KS, Rusch VW, Crowley JJ: Long-term survival after concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery in bulky stage IIIAN2 and IIIB non-small cell lung cancer (NSCLC): 6 years outcomes from Southwest Oncology Group Study 88-05. Proc Am Soc Clin Oncol 1999; 18:467a.
5. Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C, Chen Y, Livingston RB, Feins RH, Gandara DR, Fry WA, Darling G, Johnson DH, Green MR, Miller RC, Ley J, Sause WT, Cox JD: Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009; 374: 379-386.
6. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials -Non-small Cell Lung Cancer Collaborative Group. BMJ 1995; 311: 899-909.
7. Curran WJ, Scott CB, Langer CJ et al.: Longterm benefit is observed in a phase III comparison of sequential vs. concurrent chemoradiation for patients with unresected stage III NSCLC: RTOG 9410 (abstract 2499). Proc Am Soc Clin Oncol 2003; 22:621.
8. Fournel P, Robinet G, Thomas P, Souquet PJ, Lena H, Vergnenegre A, Delhoume JY, Le Treut J, Silvani JA, Dansin E, Bozonnat MC, Daures JP, Mornex F, Perol M: Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 2005; 23: 5910-5917.
9. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III nonsmall-cell lung cancer. J Clin Oncol 1999; 17: 2692-2699.
10. Zatloukal P, Petruzelka L, Zemanova M, Havel L, Janku F, Judas L, Kubik A, Krepela E, Fiala P, Pecen L: Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced nonsmall cell lung cancer: a randomized study. Lung Cancer 2004; 46: 87-98.
11. Belani CP, Wang W, Johnson DH, Wagner H, Schiller J, Veeder M, Mehta M: Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol 2005; 23: 3760-3767.
12. Schild SE, Stella PJ, Geyer SM, Bonner JA, Marks RS, McGinnis WL, Goetz SP, Kuross SA, Mailliard JA, Kugler JW, Schaefer PL, Jett JR: Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002; 54: 370-378.
13. Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP: Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003; 21: 3016-3024.
14. Georgoulias V, Ardavanis A, Agelidou A, Agelidou M, Chandrinos V, Tsaroucha E, Toumbis M, Kouroussis C, Syrigos K, Polyzos A, Samaras N, Papakotoulas P, Christofilakis C, Ziras N, Alegakis A: Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial. J Clin Oncol 2004; 22: 2602-2609.
15. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
16. Mudad R, Ramsey M, Kovitz K, Curiel TJ, Hartz R, Nedzi LL, Weiner RS, Zakris EL: Concomitant weekly docetaxel, cisplatin and radiation therapy in locally advanced non-small cell lung cancer: a dose finding study. Lung Cancer 2003; 39: 173-177.
17. Wu HG, Bang YJ, Choi EK, Ahn YC, Kim YW, Lim TH, Suh C, Park K, Park CI: Phase I study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002; 52: 75-80.
18. Yamamoto N, Nishimura Y, Nakagawa K, Matsui K, Fukuoka M: Phase I/II study of weekly docetaxel dose escalation in combination with fixed weekly cisplatin and concurrent thoracic radiotherapy in locally advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2006; 58: 285-291.
19. Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat MC, Uitterhoeve A, Wang X, Stewart L, Arriagada R, Burdett S, Pignon JP: Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 2181-2190.
20. Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre M, Lacombe-Terrier MJ, Douillard JY, Laplanche A: Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-smallcell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991; 83: 417-423.
21. Lopez-Encuentra A, Bulzebruck H, Feinstein AR, Motta G, Mountain CF, Naruke T, Sanchez JM, Tsuchiya R, Wittekind C: Tumor staging and classification in lung cancer: summary of the international symposium -Madrid, Spain, 3-4 December 1999. Lung Cancer 2000; 29: 79-83.
22. CTC-AE CTEP: Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0. DCTD, NCI, NIH, DHHS, 2006.
23. Rami-Porta R, Wittekind C, Goldstraw P: Complete resection in lung cancer surgery: proposed definition. Lung Cancer 2005; 49: 25-33.
24. Duffaud F, Therasse P: New guidelines to evaluate the response to treatment in solid tumors (in French). Bull Cancer 2000; 87: 881-886.
25. Kiura K, Ueoka H, Segawa Y, Tabata M, Kamei H, Takigawa N, Hiraki S, Watanabe Y, Bessho A, Eguchi K, Okimoto N, Harita S, Takemoto M, Hiraki Y, Harada M, Tanimoto M: Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer. Br J Cancer 2003; 89: 795-802.
26. Kaya AO, Buyukberber S, Benekli M, Coskun U, Sevinc A, Akmansu M, Yildiz R, Ozturk B, Yaman E, Kalender ME, Orhan O, Yamac D, Uner A: Concomitant chemoradiotherapy with cisplatin and docetaxel followed by surgery and consolidation chemotherapy in patients with unresectable locally advanced non-small cell lung cancer. Med Oncol 2010; 27: 152-157.
27. Tawfik HA, Taha Ael H, Attia GA: Induction docetaxel and cisplatin followed by weekly docetaxel and cisplatin with concurrent radiotherapy in locally advanced stage III non small cell lung cancer (LA-NSCLC) -a phase II study. J Egypt Natl Canc Inst 2007; 19: 15-20.
28. Rodriguez N, Algara M, Foro P, Lacruz M, Reig A, Membrive I, Lozano J, Lopez JL, Quera J, Fernandez-Velilla E, Sanz X: Predictors of acute esophagitis in lung cancer patients treated with concurrent three-dimensional conformal radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys 2009; 73: 810-817.
29. Wei X, Liu HH, Tucker SL, Liao Z, Hu C, Mohan R, Cox JD, Komaki R: Risk factors for acute esophagitis in non-small-cell lung cancer patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2006; 66: 100-107.
30. Yuan S, Sun X, Li M, Yu J, Ren R, Yu Y, Li J, Liu X, Wang R, Li B, Kong L, Yin Y: A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer. Am J Clin Oncol 2007; 30: 239-244.
31. Senan S, De Ruysscher D, Giraud P, Mirimanoff R, Budach V: Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. Radiother Oncol 2004; 71: 139-146.
32. Senan S, Cardenal F, Vansteenkiste J, Stigt J, Akyol F, De Neve W, Bakker J, Dupont JM, Scagliotti GV, Ricardi U, van Meerbeeck JP: A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin-docetaxel, plus radical concurrent chemoradiotherapy with cisplatin-docetaxel, in patients with unresectable locally advanced non-small-cell lung cancer. Ann Oncol 2011; 22: 553-558.
33. Fernandes AT, Shen J, Finlay J, Mitra N, Evans T, Stevenson J, Langer C, Lin L, Hahn S, Glatstein E, Rengan R: Elective nodal irradiation (ENI) vs. involved field radiotherapy (IFRT) for locally advanced non-small cell lung cancer (NSCLC): a comparative analysis of toxicities and clinical outcomes. Radiother Oncol 2010; 95: 178-184.
34. Aydiner A, Sen F, Saglam EK, Oral EN, Eralp Y, Tas F, Toker A, Dilege S: Induction chemotherapy with triweekly docetaxel and cisplatin followed by concomitant chemoradiotherapy with or without surgery in stage III non-small-cell lung cancer: a phase II study. Clin Lung Cancer 2011; 12: 286-292.
35. Gandara DR, Chansky K, Albain KS, Leigh BR, Gaspar LE, Lara PN Jr, Burris H, Gumerlock P, Kuebler JP, Bearden JD 3rd, Crowley J, Livingston R: Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003; 21: 2004-2010.
36. Komaki R, Seiferheld W, Ettinger D, Lee JS, Movsas B, Sause W: Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable nonsmall-cell lung cancer: long-term follow-up of RTOG 92-04. Int J Radiat Oncol Biol Phys 2002; 53: 548-557.
37. Hanna N, Neubauer M, Yiannoutsos C, Mc-Garry R, Arseneau J, Ansari R, Reynolds C, Govindan R, Melnyk A, Fisher W, Richards D, Bruetman D, Anderson T, Chowhan N, Nattam S, Mantravadi P, Johnson C, Breen T, White A, Einhorn L: Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and US Oncology. J Clin Oncol 2008; 26: 5755-5760.
38. Green MR, West H, Socinski MA, Willey J, Daniels L, Lemke K, Rafferty G, Iovino L: Impact of the ASCO 2007 presentation of HOG Lun 01-24/USO-023 on the prescribing plans of American medical oncologists for patients with stage IIIB non-small cell lung cancer. J Thorac Oncol 2009; 4: 983-987.
39. Vokes EE, Herndon JE, Kelley MJ, Cicchetti MG, Ramnath N, Neill H, Atkins JN, Watson DM, Akerley W, Green MR: Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007; 25: 1698-1704.
40. Fournel P, Vergnenegre A, Robinet G, Lena H, Gervais R, Le Caer H, Souquet PJ, Chavaillon JM, Chouaid C, Martel-Lafay I: Induction (ICT) or consolidation chemotherapy (CT) with cisplatin (C) and paclitaxel (P) plus concurrent chemo-radiation (CT/TRT) with cisplatin and vinorelbine (V) for unresectable non-small cell lung cancer (NSCLC) patients (pts): randomized phase II trial GFPC-GLOT-IFCT 02-01. Abstracts ASCO Meet, Atlanta, 2006, vol 24, pp 7048.
41. Biesma B, Manegold C, Smit HJ, Willems L, Legrand C, Passioukov A, van Meerbeeck JP, Giaccone G: Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 nonsmall cell lung cancer: a phase II study of the European organization for research and treatment of cancer (EORTC 08984). Eur J Cancer 2006; 42: 1399-1406.
42. Garrido P, Rosell R, Massuti B, Cardenal F, Alberola V, Domine M, Maeztu I, Ramos A, Arellano A: Predictors of long-term survival in patients with lung cancer included in the randomized Spanish Lung Cancer Group 0008 phase II trial using concomitant chemoradiation with docetaxel and carboplatin plus induction or consolidation chemotherapy. Clin Lung Cancer 2009; 10: 180-186.